LIVE

AGGREGATED External reporting by Bloomberg. This page summarizes the publisher's feed entry; the full article is on www.bloomberg.com.

Novartis Abandons Heart Drug After Surprising Failure in Key Study

BLOOMBERG · Fabienne Kinzelmann and Robert Langreth ·

Novartis AG is largely abandoning an experimental drug analysts once considered a potential blockbuster after a study found it had little promise for preventing heart attacks and cardiovascular deaths.

READ THE ORIGINAL AT BLOOMBERG ↗ MORE FROM THIS SOURCE

RELATED REPORTING